Pular para o conteúdo principal
Ranking Invest

AVIR - Atea Pharmaceuticals, Inc.

Segmento: HealthcareAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Análise Ranking Invest

Valuation estimado
-8,76%
-$ 325.39 Mi
Valor de Mercado
$ 425.89 Mi
Desconto (AV)-230.9%
IVR
-0.76A companhia vale -0,76 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-1.26O valuation alternativo equivale a -126% do valor de mercado da companhia.
MLL
-1.26O lucro líquido dos controladores em 16 trimestres equivale a -126% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 204.16 Mi

Dívida Líquida

-$ 76.55 Mi

L4T

-$ 165.29 Mi

Indicadores Básicos

ROE

-80.96%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.19

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

F-4.90

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.37

DIV/L4T

0.46

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.